Clinical Trials · NCT07521631
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrollment
- 372
- Start date
- Mar 2026
- Locations
- 1 site, China
- Primary endpoint
- Primary Outcome